Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
(NASDAQ: SLDB) Delayed: 8.79 +0.49 (5.90%)
Previous Close $8.30    52 Week High $ 
Open $8.19    52 Week Low $ 
Day High $9.19    P/E N/A 
Day Low $8.13    EPS $ 
Volume 3,142,730